Medicinal Treatment and Drawbacks
Treatment for peptic ulcer is dependent on the underlying cause of the ulcer. These include making lifestyle changes such as stopping alcohol or tobacco consumption, limiting use of NSAIDs, medications and/or surgical procedures.
Ulcer medications include:
1) Antibiotics – for elimination of H.pylori bacteria
If H. pylori infection is detected in the digestive tract, a combination of antibiotics may be recommended by the doctor to eliminate the bacteria. These antibiotics may include amoxicillin (Amoxil), clarithromycin (Biaxin), metronidazole (Flagyl), tinidazole (Tindamax), tetracycline (Tetracycline HCL) and levofloxacin (Levaquin). The choice of antibiotic is determined by the location of infection and the present antibiotic resistance rate of the person. Antibiotics are likely prescribed for one to two weeks along with medications such as proton-pump inhibitor (PPI) to reduce gastric acid production.
Drawback of antibiotics:
Minor side effects such as diarrhoea or stomach upset may be experienced from antibiotic treatment. Further medical attention is required if serious discomfort continues and does not improve over time.
2) PPIs – block gastric acid production and support healing
If H. pylori infection is not detected in peptic ulcer diagnosis, then proton pump inhibitors (PPIs) may be prescribed for up to eight weeks to reduce gastric acid production and promote natural healing of the ulcer. PPIs drugs reduce gastric acid by blocking the action of gastric acid-producing cells. Since gastric acid is a prerequisite for the formation of most ulcers, the ulcers would be able to heal if not a large amount of acid is present. PPIs are commonly prescribed for peptic ulcers, acid reflux (GERD), dyspepsia (indigestion) and peptic oesophagitis (severe GERD with damage to the esophageal mucosa). The efficacy of PPIs in suppressing acid and symptomatic relief often results in long-term use of these drugs. PPIs include prescription and over-the-counter drugs such as omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), esomeprazole (Nexium) and pantoprazole (Protonix).
Video on the acid-reducing mechanism of PPIs
Drawback of PPIs:
PPIs are popular options to help patients address gastric acid-related symptoms such as acid reflux and heartburn. Nonetheless, studies have associated these seemingly ‘harmless’ drugs to a number of significant medical problems.
i) Impaired digestion and nutrient absorption
When PPIs reduce gastric acid in the stomach, food cannot be digested properly. Undigested or partially digested food that moves into the small intestine would not be properly absorbed into the body and the full benefit of the nutrients from the food would be compromised as well.
Gastric acid is an essential defence against harmful bacteria in the stomach. PPI users whose gastric acid production is reduced by the drugs are vulnerable to infections such as Clostridium difficile.
In addition, PPIs also turn off the body’s proton pump (that makes hydrogen required for producing gastric acid) when the drug is administered. Upon completion of treatment and PPI withdrawn, most people could not initiate the making of hydrogen for up to 3 weeks. During this period when the level of gastric acid is low, users are exposed to an increased risk of being re-infected by H. pylori.
iii) Rebound acid hypersecretion and drug dependency
Withdrawal from PPI treatment is linked to a clinically significant increase in acid production to above pre-treatment levels, this is known as rebound acid hypersecretion. Some people with no history of acid-related symptoms such as acid regurgitation, heartburn and indigestion, may develop such symptoms for the first time after they stop their eight-week PPI treatment.
Rebound acid hypersecretion is speculated to be an excessive production of gastrin (a gastric acid-stimulating hormone) which is not apparent during PPI treatment but appears after the drug is stopped. This results in a return of symptoms for many patients after discontinuation of PPI treatment. Some people may have difficulty withdrawing from PPI treatment, and hence lead to long-term dependency on the medication. PPIs is unable to recognise and treat the underlying root cause of gastric symptoms.
iv) Increased risk of dementia
A recent study has revealed a link between PPIs and an increased risk of dementia in older patients. 40% of subjects aged 75 years and older who did not have dementia at the start of the studies were diagnosed with dementia, with 59% of them diagnosed with at least two different types of dementia (Gomm W et al., 2016).
This data is also in line with animal testing in which the use of PPIs has increased the levels of amyloid β (the hallmark brain protein for dementia) in the brains of mice. Avoidance of PPIs drug may hinder the development of dementia.
v) Increased risk of kidney disease
The use of PPIs has been associated to an increased risk of chronic kidney disease (CKD), CKD progression, and end-stage renal disease (ESRD). Analysis also revealed that the longer the duration of PPIs use, the greater the risk of renal outcomes (Xie Y et al., 2016). Another study also reported that those who took PPIs are associated with a significant 35% increase in CKD risk, compared to those who had never taken PPIs.
vi) Increased risk of heart attack
Prolonged use of PPIs has been linked to a slight elevated risk of heart attack (Shah NH et al., 2015). Researchers found that PPI users were 16 – 21% more likely to experience a heart attack, compared to those with chronic acid reflux but were not taking the drugs. Another study suggests that PPIs can disrupt normal blood vessel function, which could elevate the risk of heart attacks.
vii) Increased risk of bone fracture
Long-term PPI treatment has been associated with an increased occurrence of bone fracture (Ito T & Jensen RT, 2010). Further investigations are required to examine the possible effects of chronic acid suppression by PPIs on the absorption of key vitamins and nutrients.
ix) Increased risk of pneumonia
PPIs have been associated with an increased risk of pneumonia (Herzig SJ et al. 2009).
3) H2 blockers – block gastric acid production
Acid blockers, also known as histamine (H2) blockers, obstruct the chemical pathways that allow histamine to trigger the parietal cells of the stomach (that produce gastric acid), thereby reducing the amount of gastric acid. H2 blockers are commonly prescribed to soothe symptoms of acid reflux, relieve ulcer pain and promote healing. Prescribed or over-the-counter H2 blockers include ranitidine (Zantac), famotidine (Pepcid), cimetidine (Tagamet) and nizatidine (Axid).
Drawback of H2 blockers:
Long-term acid suppression by H2 blockers may lead to cancerous changes in the stomach if H. pylori infection is not treated. Tachyphylaxis, a fast declining response to successive doses of H2 blockers has been observed, suggesting that pharmacologic tolerance can reduce the long-term effectiveness of these medications. In addition, H2 blockers are associated with an increased risk for pneumonia. If the root cause of symptoms is not treated, ulcer complications such as perforation, bleeding and others may develop.
4) Antacids – neutralise gastric acid
Antacids neutralise existing gastric acid and this can provide rapid pain relief. This type of medication does not heal the ulcer and is only a temporary solution to a long-term problem. Many brands of antacids are available and can be purchased without a prescription. Some of the commonly used antacid chemical combinations are aluminium hydroxide, magnesium carbonate and magnesium trisilicate.
Drawback of antacids:
Long-term use of antacids is associated with some health problems such as poor digestion and decreased absorption of nutrients such as vitamin C, iron, calcium, magnesium, zinc, as well as increased risk of gastrointestinal infections. Antacids have also been associated with different side effects, depending on the main ingredients.
|Type of antacid||Neutralising power||Undesirable side effects|
|Sodium bicarbonate||Low||Fluid retention, alkalosis (excessive blood alkalinity)|
|Magnesium hydroxide||High||Diarrhoea, magnesium toxicity|
|Aluminium hydroxide||Modest||Constipation, drug or phosphate binding which inhibits absorption|
|Calcium carbonate||Very high||Acid rebound|
5) Medications that protect the linings of stomach and small intestine
Medications known as cytoprotective agents may be prescribed to help protect the tissues that line stomach and small intestine. Among the prescribed medications are sucralfate (Carafate) and misoprostol (Cytotec).
Drawback of cytoprotective agents:
The use of sucralfate and misoprostol medications may cause side effects such as dizziness, headache, diarrhoea and nausea.